HK1166077A1 - Resorcinol derivatives as hsp90 inhibitors hsp90 - Google Patents
Resorcinol derivatives as hsp90 inhibitors hsp90Info
- Publication number
- HK1166077A1 HK1166077A1 HK12106799.6A HK12106799A HK1166077A1 HK 1166077 A1 HK1166077 A1 HK 1166077A1 HK 12106799 A HK12106799 A HK 12106799A HK 1166077 A1 HK1166077 A1 HK 1166077A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hsp90
- resorcinol derivatives
- inhibitors
- hsp90 inhibitors
- resorcinol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09158367 | 2009-04-21 | ||
| PCT/EP2010/055026 WO2010121963A1 (fr) | 2009-04-21 | 2010-04-16 | Dérivés du résorcinol comme inhibiteurs de la hsp90 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1166077A1 true HK1166077A1 (en) | 2012-10-19 |
Family
ID=42270238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12106799.6A HK1166077A1 (en) | 2009-04-21 | 2012-07-11 | Resorcinol derivatives as hsp90 inhibitors hsp90 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8993556B2 (fr) |
| EP (1) | EP2421833B1 (fr) |
| JP (1) | JP5731479B2 (fr) |
| CN (1) | CN102438988B (fr) |
| AR (1) | AR076645A1 (fr) |
| ES (1) | ES2533954T3 (fr) |
| HK (1) | HK1166077A1 (fr) |
| TW (1) | TW201041856A (fr) |
| WO (1) | WO2010121963A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800936A1 (fr) * | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Conjugues d'haptene pour une detection de cible |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014144715A1 (fr) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Imagerie cardiaque à ciblage hsp90 et traitement associé |
| CA2915975A1 (fr) * | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Procedes de modulation de l'activite de cftr |
| BR112017005313A2 (pt) | 2014-09-17 | 2017-12-05 | Memorial Sloan Kettering Cancer Center | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 |
| US9855249B2 (en) | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| CN109422690A (zh) * | 2017-08-31 | 2019-03-05 | 浙江省化工研究院有限公司 | 一种制备1-烷基-3-烷基吡唑-5-甲酸酯的方法 |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| CN109364045B (zh) * | 2018-10-21 | 2020-08-21 | 郑州大学第一附属医院 | 一种热休克蛋白90抑制剂及在肝癌治疗方面的应用 |
| JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
| EP3986890B1 (fr) | 2019-06-18 | 2023-11-15 | Pfizer Inc. | Dérivés de benzisoxazole sulfonamide |
| TWI771766B (zh) * | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| MX2023001014A (es) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Composiciones farmaceuticas que comprenden venglustat. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2073284B1 (fr) | 1969-12-23 | 1973-07-13 | Ferlux | |
| DE2250343A1 (de) | 1972-10-13 | 1974-04-18 | Thiemann Chem Pharm Fab | 4,6-disubstituierte resorcinverbindungen |
| IL111613A0 (en) | 1993-11-12 | 1995-01-24 | Rhone Poulenc Rorer Ltd | Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them |
| US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| MXPA04005864A (es) * | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| SI1611112T1 (sl) | 2003-02-11 | 2012-12-31 | Vernalis (R&D) Limited | Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| WO2005063222A1 (fr) | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de proteines de la famille hsp90 |
| JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| JP2006306755A (ja) * | 2005-04-27 | 2006-11-09 | Nippon Kayaku Co Ltd | 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤 |
| BRPI0807219A2 (pt) * | 2007-02-08 | 2015-05-26 | Synta Pharmaceuticals Corp | Composto de tiazol que modulam a atividade de hsp90 |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
-
2010
- 2010-04-16 EP EP10714268.9A patent/EP2421833B1/fr active Active
- 2010-04-16 WO PCT/EP2010/055026 patent/WO2010121963A1/fr active Application Filing
- 2010-04-16 CN CN201080017562.7A patent/CN102438988B/zh active Active
- 2010-04-16 JP JP2012506450A patent/JP5731479B2/ja active Active
- 2010-04-16 US US13/264,888 patent/US8993556B2/en active Active
- 2010-04-16 ES ES10714268.9T patent/ES2533954T3/es active Active
- 2010-04-19 AR ARP100101286A patent/AR076645A1/es unknown
- 2010-04-19 TW TW099112135A patent/TW201041856A/zh unknown
-
2012
- 2012-07-11 HK HK12106799.6A patent/HK1166077A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102438988A (zh) | 2012-05-02 |
| WO2010121963A1 (fr) | 2010-10-28 |
| JP5731479B2 (ja) | 2015-06-10 |
| US8993556B2 (en) | 2015-03-31 |
| US20120046266A1 (en) | 2012-02-23 |
| AR076645A1 (es) | 2011-06-29 |
| CN102438988B (zh) | 2015-06-24 |
| JP2012524743A (ja) | 2012-10-18 |
| ES2533954T3 (es) | 2015-04-16 |
| EP2421833A1 (fr) | 2012-02-29 |
| TW201041856A (en) | 2010-12-01 |
| EP2421833B1 (fr) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1166077A1 (en) | Resorcinol derivatives as hsp90 inhibitors hsp90 | |
| HK1143367A1 (en) | Quinazolin-oxime derivatives as hsp90 inhibitors hsp90 - | |
| HK1173142A1 (en) | N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5- | |
| HK1172893A1 (en) | 5-fluoropyrimidinone derivatives 5- | |
| IL219087A0 (en) | Benzimidazole-imidazole derivatives | |
| ZA201005435B (en) | Oxim derivatives as hsp90 inhibitors | |
| EP2486039A4 (fr) | Dérivés de purine convenant comme inhibiteurs de hsp90 | |
| IL216007A0 (en) | Isoxazole-pyridine derivatives | |
| IL215109A0 (en) | Isoxazole-pyridazine derivatives | |
| IL214941A0 (en) | Isoxazole-pyrazole derivatives | |
| IL213927A0 (en) | Deoxyactagardine derivatives | |
| IL218967A0 (en) | Phenyloxadiazole derivatives as pgds inhibitors | |
| HK1172894A1 (en) | N1-acyl-5-fluoropyrimidinone derivatives n1--5- | |
| HK1169623A1 (en) | Pyrazinooxazepine derivatives | |
| GB201009853D0 (en) | HSP90 inhibitors | |
| ZA201109536B (en) | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors | |
| GB0901898D0 (en) | Dual calpain-ros inhibitors | |
| IL218500A0 (en) | Apogossypolone derivatives as anticaner agents | |
| EP2488183A4 (fr) | Composition d'inhibition de tgf- comprenant des dérivés d'imidazopurine | |
| EP2512482A4 (fr) | Dérivés de 2-aldoximino-5-fluoropyrimidine | |
| GB0901900D0 (en) | Dual calpain-ros inhibitors | |
| HK1173134A1 (en) | Substituted halophenoxybenzamide derivatives | |
| GB0808286D0 (en) | Inhibitors of HSP90 | |
| IL213262A0 (en) | Tetrahydronaphthalen-2-ol derivatives | |
| GB0912499D0 (en) | Indopyl-pyridone derivatives |